Author Correction: Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors

Nature Communications

Home Author Correction: Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors

https://doi.org/10.1038/s41467-021-23082-3, Volume: 12

Article Type: Correction Article History

Publisher: Nature Publishing Group UK

Altmetric

Table of Contents

Keywords

Molecular Medicine, SARS-CoV-2, X-ray crystallography, Virology

Iketani,Forouhar,Liu,Hong,Lin,Nair,Zask,Huang,Xing,Stockwell,Chavez,and Ho: Author Correction: Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors

Correction to: Nature Communications 10.1038/s41467-021-22362-2, published online 1 April 2021.

The original version of this Article omitted the following from the Acknowledgements: Part of the research was conducted at the Northeastern Collaborative Access Team beamlines, which are funded by the National Institute of General Medical Sciences from the National Institutes of Health (P30 GM124165). This has now been corrected in both the PDF and HTML versions of the Article.